- Home
- GEN vs UTHR Comparison
GEN vs UTHR Comparison
Compare GEN & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEN
- UTHR
- Stock Information
- Founded
- GEN 1982
- UTHR 1996
- Country
- GEN United States
- UTHR United States
- Employees
- GEN N/A
- UTHR N/A
- Industry
- GEN Computer Software: Prepackaged Software
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- GEN Technology
- UTHR Health Care
- Exchange
- GEN Nasdaq
- UTHR Nasdaq
- Market Cap
- GEN 18.9B
- UTHR 14.4B
- IPO Year
- GEN N/A
- UTHR 1999
- Fundamental
- Price
- GEN $28.69
- UTHR $297.02
- Analyst Decision
- GEN Hold
- UTHR Buy
- Analyst Count
- GEN 4
- UTHR 13
- Target Price
- GEN $30.00
- UTHR $383.08
- AVG Volume (30 Days)
- GEN 4.5M
- UTHR 561.1K
- Earning Date
- GEN 08-07-2025
- UTHR 07-30-2025
- Dividend Yield
- GEN 1.68%
- UTHR N/A
- EPS Growth
- GEN 8.42
- UTHR 18.86
- EPS
- GEN 1.03
- UTHR 25.10
- Revenue
- GEN $3,935,000,000.00
- UTHR $2,994,100,000.00
- Revenue This Year
- GEN $21.37
- UTHR $14.58
- Revenue Next Year
- GEN $4.98
- UTHR $6.34
- P/E Ratio
- GEN $27.85
- UTHR $11.77
- Revenue Growth
- GEN 3.55
- UTHR 19.84
- 52 Week Low
- GEN $22.74
- UTHR $266.98
- 52 Week High
- GEN $31.72
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- GEN 43.45
- UTHR 51.32
- Support Level
- GEN $28.95
- UTHR $286.68
- Resistance Level
- GEN $30.19
- UTHR $301.75
- Average True Range (ATR)
- GEN 0.56
- UTHR 6.73
- MACD
- GEN -0.12
- UTHR 1.81
- Stochastic Oscillator
- GEN 10.13
- UTHR 77.16
About GEN Gen Digital Inc.
Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.